drugset / Trial / NCT02134080
FAAH Inhibitor Trial for Adults With Tourette Syndrome
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this trial is to examine the safety, tolerability and feasibility in the use of a FAAH inhibitor for the treatment of adults with Tourette syndrome.
Timeline
- Start
- 2014-05
- Primary completion
- 2017-03
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | REDAFAMDASTAT | Small molecule | 4 mg | Oral |